Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.79 |
| ▸ | NPC1 | O15118 | 2/20 | 0.79 |
| ▸ | RAB9A | P51151 | 2/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NT5E | P21589 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | PRKCI | P41743 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | TYK2 | P29597 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22601457 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601460 | 0.87 | LMNA (0.82) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601584 | 0.86 | LMNA (0.80) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601544 | 0.83 | LMNA (0.85) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601588 | 0.83 | LMNA (0.76) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601575 | 0.80 | LMNA (0.74) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601558 | 0.80 | LMNA (0.74) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL26074344 | 0.80 | LMNA (0.74) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL17688884 | 0.80 | LMNA (0.66) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL22601533 | 0.77 | LMNA (0.71) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | LMNA 3233/4885SMN1; SMN2 3406/4885NPC1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.